2009
Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013. Journal Of Clinical Oncology 2009, 27: 3430-3436. PMID: 19470942, PMCID: PMC4979079, DOI: 10.1200/jco.2008.18.4085.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntibiotics, AntineoplasticAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCyclophosphamideDNA Topoisomerases, Type IIDNA-Binding ProteinsDoxorubicinDrug InteractionsFluorouracilGene AmplificationHumansImmunohistochemistryReceptor, ErbB-2
2004
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars In Oncology 2004, 31: 106-146. PMID: 15717740, DOI: 10.1053/j.seminoncol.2004.09.018.Peer-Reviewed Original ResearchConceptsConventional doxorubicinBreast cancerLiposomal anthracyclinesLiposomal doxorubicinHand-foot syndromeAdvanced breast cancerMultiple phase IIConventional anthracyclinesSystemic therapyProlong survivalStandard dosesContinuous infusionToxicity profileOptimal doseActive drugCytotoxic drugsHigh dosesIntermittent scheduleWeekly scheduleAnthracyclinesNormal tissuesTrastuzumabCancerDoxorubicinNausea
2001
Liposomal anthracyclines for breast cancer
Sparano J, Winer E. Liposomal anthracyclines for breast cancer. Seminars In Oncology 2001, 28: 32-40. PMID: 11552228, DOI: 10.1016/s0093-7754(01)90197-6.Peer-Reviewed Original ResearchConceptsBreast cancerLiposomal anthracyclinesAdvanced-stage breast cancerStage breast cancerConventional anthracyclinesTLC DLiposomal daunorubicinCardiac toxicityConventional doxorubicinLiposomal doxorubicinPreclinical modelsAnthracyclinesCancer typesCytotoxic agentsNormal tissuesCancerFurther studiesChronic toxicityDoxorubicinTreatmentToxicityLiposomal doxorubicin preparationsAgentsCyclophosphamideVinorelbine